Both Accolade and Lemonade opened higher on Thursday, July 2, with the former selling more shares than expected, and the latter pricing above its raised range.

LATEST IPOS

Accolade (ACCD) opened on July 2 at $35.00. The company had priced 10.02 million shares at $22.00. The deal size was increased to 10.02 million shares of common stock from 8.75 million shares of common stock, and priced above the $19.00-$21.00 range. Goldman Sachs, Morgan Stanley, and BofA  acted as joint book running managers for the offering.

Accolade provides personalized, technology-enabled solutions that help people better understand, navigate, and utilize the healthcare system and their workplace benefits.

Lemonade (LMND) opened on July 2 at $50.06. The company had priced 11 million shares at $29.00, above the $26.00-$28.00 range. Goldman Sachs, Morgan Stanley, Allen & Co., and Barclays acted as joint book running managers for the offering. Lemonade is a tech-driven insurance company backed by Softbank (SFTBY).

Dun & Bradstreet (DNB) opened on July 1 at $25.00. The company had priced 78.3 million shares at $22.00. The deal priced above the $19.00-$21.00 range, and the deal size was increased to 78.3 million shares from 65.8 million shares offered. Goldman Sachs and BofA acted as joint book running managers for the offering. Dun & Bradstreet is a data and analytics provider.

PERFORMANCE

• Accolade ended the week at $29.70.
• After opening at $50.06, Lemonade finished the week at $69.41.
• Dun & Bradstreet ended Thursday at $27.10, after opening at $25.

UPCOMING IPOS

Among the upcoming IPOs are Juniper Wellness (JUPW), BlueCity Holdings (BLCT), Poseida Therapeutics (PSTX), InMed Pharmaceuticals (INM), and Nkarta (NKTX).

• Juniper Wellness is a functional wellness and natural health products company.
• BlueCity Holdings is an online LGBTQ community and dating platform in China.
• Poseida Therapeutics focuses on developing cell and gene therapies based on a proprietary DNA modification, gene editing, and delivery technology.
• InMed Pharmaceuticals is developing cannabinoid-based treatments for skin and eye conditions.
• Nkarta is developing natural killer-based cell therapies that treat certain types of cancer.